According to Laimei Pharmaceutical's announcement, the company signed a “Drug Marketing License Transfer Agreement” with Tianzhihai Pharmaceutical to transfer its rights such as registration approval, commercial and marketing of vitamin D₂ softgels for 28 million yuan. The transfer was paid in four installments. This transaction does not constitute a related or major asset restructuring. There is no need for review by the board of directors or shareholders' meetings, but it is subject to approval by the State Drug Administration. The deal will enrich the company's product line, but there are risks such as production during the transition period or reliance on the original holder, and product collection continues to be unselected.

According to Laimei Pharmaceutical's announcement, the company signed a “Drug Marketing License Transfer Agreement” with Tianzhihai Pharmaceutical to transfer its rights such as registration approval, commercial and marketing of vitamin D₂ softgels for 28 million yuan. The transfer was paid in four installments. This transaction does not constitute a related or major asset restructuring. There is no need for review by the board of directors or shareholders' meetings, but it is subject to approval by the State Drug Administration. The deal will enrich the company's product line, but there are risks such as production during the transition period or reliance on the original holder, and product collection continues to be unselected.